Publicacións en colaboración con investigadores/as de Novartis (Sweden) (4)

2024

  1. Capmatinib plus nazartinib in patients with EGFR-mutated non–small cell lung cancer

    European Journal of Cancer, Vol. 208

2023

  1. Effect of capmatinib on the pharmacokinetics of substrates of CYP3A (midazolam) and CYP1A2 (caffeine) in patients with MET-dysregulated solid tumours

    British Journal of Clinical Pharmacology, Vol. 89, Núm. 3, pp. 1046-1055

2022

  1. A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer

    Clinical Cancer Research, Vol. 28, Núm. 1, pp. 106-115

2019

  1. Prospective Observational Study of Pazopanib in Patients with Advanced Renal Cell Carcinoma (PRINCIPAL Study)

    Oncologist, Vol. 24, Núm. 4, pp. 491-497